Title

What is coming next for in vivo gene therapy? (HIV Cure & Gene Therapy Forum)

Code

SY22

Session Type

Symposium

Track

Not applicable

Channel

IAS+

Date Time

19 July 12:00- 12:30

Local Date Time

12:00 - 12:30 W. Europe Daylight Time

Co-Chairs:

Lynda DEE, AIDS Action Baltimore, Inc., United States
Thumbi NDUNG'U, Africa Health Research Institute, University of KwaZulu-Natal, South Africa

Presenters will deliver six "elevator pitches" to describe viral and non-viral approaches to directly engineering cells in vivo. By modifying long-lived cells such as hematopoietic stem cells and B cells, these approaches could provide immune control of the rebound-competent HIV reservoir or remission of sickle cell disease.

Presentations
Session recording

1 min	Co-chairs introduction Lynda DEE, AIDS Action Baltimore, Inc., United States Thumbi NDUNG'U, Africa Health Research Institute, University of KwaZulu-Natal, South Africa

5 min	AAV vectors targeting HSCs in vivo Christopher FINCH, CRISPR Therapeutics, United States	PDF

5 min	Development of LNP/mRNA vaccines encoding highly networked HIV epitopes Gaurav GAIHA, Ragon Institute of MGH, MIT & Harvard, United States

5 min	Targeting and modifying B cells in vivo Justin TAYLOR, Fred Hutch, United States	PDF

5 min	Lentiviral targeting of HSCs in vivo Els VERHOEYEN, CIRI/INSERM, France

5 min	Discovery and development of LNPs targeting HSCs in vivo Cory SAGO, Beam Therapeutics, United States	PDF

4 min	Targeted nucleoside-modified mRNA therapeutics Drew WEISSMAN, Perelman School of Medicine at the University of Pennsylvania, United States	PDF